SLNO - Soleno Therapeutics to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences:
| Event : |
| Jefferies Global Healthcare Conference |
| Day : |
| Wednesday, June 5, 2024 |
| Time : |
| 11:30 AM Eastern Time |
| Event : |
| Goldman Sachs 45th Annual Global Healthcare Conference |
| Day : |
| Tuesday, June 11, 2024 |
| Time : |
| 4:00 PM ET |
A live audio webcast and replay of the events will be available in the Investors section on the Company’s website at www.soleno.life .
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit www.soleno.life .
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578